ERBB2 and colorectal carcinoma: Furthermore, in the retrospective analysis done by Heppner et al. (1645 patients, stages I to IV CRC) was reported poorer OS in patients with HER2+ when compared to those without amplification, with the same results coming from the PETACC-8 study (3.8% patients with HER2+) that showed significantly lesser time to recurrence (HR 1.55; 95% CI 1.02-2.36; p=0.04) and shorter OS (HR 1.57; 95% CI 0.99-2.5; p=0.04) [15].